Business Wire

Breakthrough Discovery: British Explorer Andrew ‘Sandy’ Irvine’s Partial Remains Believed to Be Found on Mount Everest After 100 Years

11.10.2024 08:00:00 CEST | Business Wire | Press release

Share

Discovery Made by Expedition Team Led by Jimmy Chin During Mount Everest Climb for Upcoming National Geographic Documentary Film, Reported Exclusively on NatGeo.comEvidence Is First Possible Proof of Irvine’s Death Since Disappearing During 1924 Expedition With George Mallory, Whose Remains Were Found on Everest in 1999 by Conrad AnkerExclusive Photos NatGeo.com Story: https://www.nationalgeographic.com/adventure/article/sandy-irvine-body-found-everest

After 100 years of speculation surrounding his fate, the partial remains of Andrew Comyn “Sandy” Irvine are believed to have finally been discovered on Mount Everest. At age 22, Irvine vanished while attempting to conquer the world’s tallest peak on June 8, 1924, along with his climbing partner, renowned mountaineer George Mallory.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010214459/en/

A sock embroidered with "A.C. Irvine", along with a boot, has been discovered on the Central Rongbuk Glacier below the North Face of Mount Everest by a team led by Jimmy Chin. This is the first possible proof of Irvine's death since disappearing during a 1924 expedition. (credit: Jimmy Chin)

The discovery was made recently by a small team including National Geographic Explorer, photographer, Academy Award-winning director and professional climber Jimmy Chin along with climbers and filmmakers Erich Roepke and Mark Fisher. What is believed to be Irvine’s foot, encased in a sock and boot, was found on the Central Rongbuk Glacier below the North Face of Everest at a lower altitude than Mallory’s remains were located. The partial remains – identified with his name stitched into the sock – are now in the possession of the China Tibet Mountaineering Association, which is responsible for climbing permits on Everest’s northern side.

The find was reported to the Royal Geographical Society - who jointly organized Mallory and Irvine’s expedition along with the Alpine Club - which at the time was only the third British climb on Mount Everest. It was also shared with Irvine’s great niece and biographer, Julie Summers – one of many living family relatives. The Irvine family has volunteered to compare DNA test results with the remains to confirm Irvine’s identity.

“Any expedition to Everest follows in the shadow of Irvine and Mallory,” said Chin. “We certainly did. And sometimes in life the greatest discoveries occur when you aren’t even looking. This was a monumental and emotional moment for us and our entire team on the ground, and we just hope this can finally bring peace of mind to his relatives and the climbing world at large.”

“It is remarkable that this discovery was made in the centenary year of Sandy’s disappearance,” said Summers. “I have lived with this story since I was a 7-year-old when my father told us about the mystery of Uncle Sandy on Everest. The story became more real when climbers found the body of George Mallory in 1999, and I wondered if Sandy’s body would be discovered next. A quarter of a century after that discovery, it seemed extremely unlikely that anything new would be found. When Jimmy told me that he saw the name A.C. Irvine on the label on the sock inside the boot, I found myself moved to tears. It was and will remain an extraordinary and poignant moment.”

Professor Joe Smith, director of the Royal Geographical Society, said of the discovery: “As joint organiser of the 1924 Everest expedition (with the Alpine Club), the Society deeply appreciates the respect Jimmy Chin’s team has shown Sandy Irvine’s remains and their sensitivity toward Sandy’s family members and others connected to that expedition. Sandy was an exceptional figure and made a significant contribution to our understanding of Everest and the Himalaya. This discovery of his remains provides an element of closure for his relatives and the wider mountaineering community, and we are grateful to Jimmy and his team for enabling this and ensuring Sandy is in safe hands. The Society will continue to assist Jimmy, his team and Sandy’s extended family during what will inevitably be a period of intense global interest.”

Irvine and Mallory were British mountaineers who disappeared in 1924 during an expedition organized by the Royal Geographical Society and Alpine Club to be the first to summit Everest. The mystery of whether they reached the summit before their death has intrigued climbers and historians for decades. Mallory’s body was discovered in 1999 by climber Conrad Anker, but until now, Irvine’s remains had never been found.

The team’s climb was funded by National Geographic Documentary Films for an upcoming documentary directed and produced by the Academy Award- and the BAFTA Award-winning team behind “Free Solo,” E. Chai Vasarhelyi and Chin, and their banner Little Monster Films.

Irvine Family Statement on the Discovery:

“The Irvine family is deeply moved to hear of the discovery of partial remains of Sandy Irvine. We are grateful to the mountaineering and film team, led by Jimmy Chin, who made the discovery and who have treated it with respect and professionalism. We are happy that the remains are now in the hands of the CTMA. Sandy Irvine was the youngest member of the 1924 Mount Everest expedition and was lost on the upper slopes of the mountain with George Mallory when the two disappeared on 8 June 1924.”

ABOUT JIMMY CHIN

Chin is a professional climber, skier, mountaineer, 20-year member of The North Face Athlete Team and National Geographic Explorer. Consistently over the past 20 years, Chin has led or participated in cutting-edge climbing and ski mountaineering expeditions to all seven continents and participated in the first and only American ski descent from the summit of Mount Everest. He is also a filmmaker and National Geographic photographer. He has worked with many of the greatest explorers, adventurers and athletes of our time, documenting their exploits in the most challenging conditions and locations in the world. Together with his wife, Elizabeth Chai Vasarhelyi, he has co-directed the films “Meru,” “Free Solo,” “The Rescue,” “Wild Life,” “Return To Space,” and their first scripted feature, “Nyad.” Their next documentary feature, “Endurance” premieres this weekend at the BFI London Film Festival. Chin and Vasarhleyi won the Best Documentary Oscar® in 2019 for “Free Solo.”

Exclusive Photos
NatGeo.com Story:
https://www.nationalgeographic.com/adventure/article/sandy-irvine-body-found-everest

View source version on businesswire.com: https://www.businesswire.com/news/home/20241010214459/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye